How to apply for bedaquiline to treat drug-resistant tuberculosis

Bedaquiline (Bedaquiline) is a new anti-tuberculosis drug mainly used to treat multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant tuberculosis (XDR-TB). It is an ATP synthase inhibitor and plays a bactericidal effect by inhibiting the energy metabolism of Mycobacterium tuberculosis. Due to its unique mechanism of action, it is of great significance for cases where traditional drug treatments fail or are resistant. However, due to potential adverse reactions and risks of cardiotoxicity, the use of bedaquiline is strictly restricted, so the application process is relatively complicated and needs to follow a series of medical and ethical procedures.

In China, if a patient is diagnosed with multidrug-resistant or extensively drug-resistant tuberculosis and fails to respond to standard second-line anti-tuberculosis regimens, doctors can recommend the use of bedaquiline after evaluation based on tuberculosis prevention and treatment guidelines. Patients need to undergo further drug resistance gene testing and drug sensitivity analysis at designated hospitals to ensure clear indications. In terms of drug availability, bedaquiline has been approved by the State Food and Drug Administration and is produced by Johnson & Johnson. It can be prescribed in some large public hospitals and designated tuberculosis institutions. Patients are also required to sign an informed consent form and use it under close monitoring by doctors, including regular electrocardiograms, liver and kidney function monitoring, etc.

In addition, in areas with limited resources or where drugs are not directly available, you can apply for assistance channels through national or local tuberculosis projects, such as Chinese Centers for Disease Control and Prevention cooperation projects, Global Fund assistance programs, etc., or obtain drugs through "patient-centered channels" approved by medical innovation cooperation organizations (such asMSF, WHO). In rare cases, special import applications can also be made through the International Public Welfare Drug Program, but this process takes a long time and requires strict medical evaluation.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline